Thursday, December 12, 2024, 7:15 PM – 9:15 PM CT (8:15 PM – 10:15 PM ET) | San Antonio, Texas

Rounds with the Investigators: Compelling Teaching Cases Focused on the Management of Metastatic Breast Cancer

Part 3 of a 3-Part CME Satellite Symposium Series in Partnership with the 2024 San Antonio Breast Cancer Symposium®

Location
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, Texas
Hotel Phone: (210) 223-1000

Program Schedule — Central Time
7:00 PM – 7:15 PM — Registration
7:15 PM – 9:15 PM — Educational Dinner Meeting
Buffet will open at 7:00 PM CT.

Meeting Room
Grand Ballroom G-M (Third Floor)


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in San Antonio, preregistration is required as seating is limited.  
 
Faculty
Erika Hamilton, MD
Director, Breast Cancer Research Program
Sarah Cannon Research Institute
Nashville, Tennessee

Kevin Kalinsky, MD, MS
Professor
Department of Hematology and Medical Oncology
Emory University School of Medicine
Director, Division of Medical Oncology
Director, Glenn Family Breast Center
Winship Cancer Institute of Emory University
Atlanta, Georgia

Ian E Krop, MD, PhD
Associate Cancer Center Director for Clinical Research
Director, Clinical Trials Office
Yale Cancer Center
New Haven, Connecticut


Joyce O’Shaughnessy, MD
Celebrating Women Chair in
Breast Cancer Research
Baylor University Medical Center
Chair, Breast Disease Committee
Sarah Cannon Research Institute
Dallas, Texas

Sara M Tolaney, MD, MPH
Chief, Division of Breast Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Daiichi Sankyo Inc. This is not an official program of the San Antonio Breast Cancer Symposium®.
Program Schedule — Central Time
7:00 PM – 7:15 PM — Registration
7:15 PM – 9:15 PM — Educational Dinner Meeting
Buffet will open at 7:00 PM CT.

Discussion Topics

  • MODULE 1: Optimizing the Care of Patients with HER2-Positive Metastatic Breast Cancer (mBC)
  • MODULE 2: Selection and Sequencing of Therapy for Patients with Metastatic Triple-Negative Breast Cancer
  • MODULE 3: Integrating Novel Agents and Approaches into the Management of Endocrine-Resistant HR-Positive mBC
  • MODULE 4: Tolerability Considerations with the Use of Common Therapies
  • MODULE 5: Other Important Care Considerations for Patients with mBC

Target Audience
This activity is intended for medical oncologists, breast surgeons, radiation oncologists and other healthcare professionals involved in the diagnosis and treatment of breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Consider biological, patient, psychosocial and treatment-related factors to personalize the selection and sequencing of therapy for metastatic breast cancer (mBC).
  • Review and use published research findings to effectively inform the selection and sequencing of available therapeutic agents and regimens for patients with HER2-positive mBC.
  • Review published research data supporting the use of chemotherapy in combination with anti-PD-1/PD-L1 antibodies for patients with metastatic triple-negative breast cancer (mTNBC), and use this information to make appropriate treatment recommendations.
  • Evaluate published research findings, clinical factors (eg, age, performance status, prior therapeutic exposure, HER2-low status) and personal preferences in the selection and sequencing of available therapeutic agents for patients with PD-L1-negative mTNBC or those with PD-L1-positive mTNBC who experience disease progression on front-line chemoimmunotherapy.
  • Discuss available research establishing the efficacy of PARP inhibitors in patients with mBC harboring BRCA or other homologous recombination repair pathway mutations, and identify appropriate candidates for treatment with these agents.
  • Define endocrine resistance in patients with HR-positive mBC, and integrate available nonhormonal therapies into the management of relapsed/refractory disease.
  • Review published Phase III research documenting the efficacy of TROP2-directed antibody-drug conjugates for mBC to determine the current and potential clinical applicability of this approach.
  • Assess the biological rationale for, early data with and ongoing clinical trials evaluating other novel agents and treatment strategies in development for mBC.

CME Credit Form
A CME credit link will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures to be provided.

FACULTY
To be announced.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Daiichi Sankyo Inc.

San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

Meeting Room
Grand Ballroom G-M (Third Floor)

Directions
The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2024 San Antonio Breast Cancer Symposium is taking place.

 
This activity is intended for medical oncologists, breast surgeons, radiation oncologists and other healthcare professionals involved in the diagnosis and treatment of breast cancer.

There is no fee to participate in this hybrid event. In order to attend the in-person symposium in San Antonio, you must also be registered to attend the 2024 San Antonio Breast Cancer Symposium®.

IN-PERSON Registration for clinicians in practice/healthcare professionals

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

IN-PERSON Registration
for clinicians »
IN-PERSON Registration for other/industry professionals*

Please note, a limited number of seats are available to other/industry professionals on a first come, first served basis.

IN-PERSON Registration
for nonclinicians »
 
* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
LIVE WEBCAST Registration for all professionals

Please note, we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

REGISTRATION FOR WEBCAST »
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 15 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.